NZ505951A - A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening - Google Patents

A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening

Info

Publication number
NZ505951A
NZ505951A NZ505951A NZ50595199A NZ505951A NZ 505951 A NZ505951 A NZ 505951A NZ 505951 A NZ505951 A NZ 505951A NZ 50595199 A NZ50595199 A NZ 50595199A NZ 505951 A NZ505951 A NZ 505951A
Authority
NZ
New Zealand
Prior art keywords
drug
cyclodextrin
enhancing
opening
heterocycloc
Prior art date
Application number
NZ505951A
Inventor
Thorsteinn Loftsson
Mar Masson
Einar Stefansson
Original Assignee
Cyclops Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclops Ehf filed Critical Cyclops Ehf
Publication of NZ505951A publication Critical patent/NZ505951A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for enhancing the complexation efficiency of a benzodiazepine with cyclodextrin comprising: complexing benzodiazepine with cyclodextrin in an aqueous medium at a pH level below 5 and allowing the resultant complexation medium to equilibrate for sufficient time to effect chemically reversible ring-opening of at least 1% by weight of benzodiazepine, an d further comprising detecting the presence of the ring-opened form of benzodiazepine.
NZ505951A 1998-02-23 1999-02-16 A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening NZ505951A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7554498P 1998-02-23 1998-02-23
PCT/IS1999/000003 WO1999042111A1 (en) 1998-02-23 1999-02-16 High-energy cyclodextrin complexes

Publications (1)

Publication Number Publication Date
NZ505951A true NZ505951A (en) 2003-02-28

Family

ID=22126450

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ505951A NZ505951A (en) 1998-02-23 1999-02-16 A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening

Country Status (7)

Country Link
EP (1) EP1067942A1 (en)
JP (1) JP2003522207A (en)
AU (1) AU759280C (en)
CA (1) CA2320772A1 (en)
IS (1) IS5572A (en)
NZ (1) NZ505951A (en)
WO (1) WO1999042111A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7937500A (en) * 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
DE60115217T2 (en) * 2000-03-28 2006-07-20 Farmarc Nederland B.V. ALPRAZOLAM INCLUSION COMPLEXES AND ITS PHARMACEUTICAL COMPOSITIONS
PT1406633E (en) 2001-06-18 2012-01-12 Noven Pharma Enhanced drug delivery in transdermal systems
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
WO2003022270A1 (en) * 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Transdermal administration of an enalapril ester
ATE386532T1 (en) * 2002-06-13 2008-03-15 Novartis Pharma Gmbh QUATERNIZED AMMONIUM CYCLODEXTRIN COMPOUNDS
US7888328B2 (en) 2003-03-28 2011-02-15 Ares Trading S.A. Oral formulations of cladribine
AU2004311478A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
MXPA06012240A (en) 2004-04-23 2007-01-31 Cydex Inc Dpi formulation containing sulfoalkyl ether cyclodextrin.
PT2583668E (en) 2005-10-26 2015-01-05 Cydex Pharmaceuticals Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
BRPI0717460A2 (en) * 2006-10-20 2013-12-24 Icos Corp CHK1 INHIBITOR COMPOSITIONS
US20100056500A1 (en) * 2006-11-21 2010-03-04 Thitiwan Buranachokaisan Stable Parenteral Formulation
DK2152078T3 (en) 2007-04-27 2021-02-08 Cydex Pharmaceuticals Inc FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYLETHERCYCLODEXTRINE AND USE PROCEDURES
EP2106786A1 (en) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmaceutical preparation comprising permethylated cyclodextrin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US20110318474A1 (en) 2008-12-29 2011-12-29 Mark John Berry Food products enriched with methylxanthines
CN102625658B (en) 2009-05-13 2015-01-28 锡德克斯药物公司 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EP2571502B1 (en) 2010-05-19 2016-04-27 Unilever N.V. Theobromine for increasing hdl-cholesterol
EP2678320B1 (en) 2011-02-23 2018-09-19 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
DK2814849T3 (en) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Process for Preparation of Cyclodextrin Derivatives
CN110066351B (en) 2012-02-28 2022-06-14 锡德克斯药物公司 Alkylated cyclodextrin compositions and methods of making and using the same
NZ707323A (en) 2012-10-22 2018-11-30 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
CN104870001B (en) 2012-11-15 2019-01-18 赛博尔泰克股份公司 Delphinidin complex compound as anti-inflammatory or immunosupress effective component
EP2931287B1 (en) 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin for combating melanoma cells
PT3183295T (en) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
WO1999042111A1 (en) 1999-08-26
AU759280B2 (en) 2003-04-10
AU2638599A (en) 1999-09-06
EP1067942A1 (en) 2001-01-17
CA2320772A1 (en) 1999-08-26
AU759280C (en) 2004-01-22
IS5572A (en) 2000-08-16
JP2003522207A (en) 2003-07-22

Similar Documents

Publication Publication Date Title
NZ505951A (en) A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
YU47648B (en) THE MEANS OF SUSPENSION, PRESERVATION AND STORAGE OF CELLS, IN THE FIRST LINE OF ERITROCITES AND ITS APPLICATION
DK1022277T3 (en) New taxon derivatives
BG105082A (en) 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists
MY103994A (en) Recovery of oil from oil reservoirs
DK1242308T3 (en) Silica-based sunsets
HK1042496A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bishosphatase
ZA200204380B (en) Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives.
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
DE69108191T2 (en) Hydraulic shock absorber for use in the borehole.
MA26919A1 (en) 5-CHLORO-3- (4-METHANESULFONYLPHENYL) -6'-METHYL- [2,3 '] BIPYRIDINYL IN A PURE CRYSTALLINE FORM AND SYNTHESIS PROCESS.
ZA200107849B (en) Water treatment system and method using permeable embankments, weirs, walls, or the like.
YU33602A (en) Solutions containing epinastine
ZA200300744B (en) Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same.
MXPA02007956A (en) Method for preparing functionalised polyalkylenimines, composition containing same and uses thereof.
NO971173D0 (en) Preservative
WO2001010408A3 (en) Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
AU5227200A (en) Method for separating in an aqueous medium lanthanides and/or actinides by combined complexing-nanofiltration, and novel complexing agents therefor
ITRE990028A0 (en) CHELATED FOOD SUPPLEMENT FOR AGRO-ZOOTECHNICAL USE, AND METHOD FOR OBTAINING THE SAME.
HUP0300495A3 (en) Optically active structure for personalizing cards and the like, and method for the production thereof
AU7211300A (en) Method for producing aqueous alkaline solutions or reduced indigoid dyes
EP1102284A4 (en) Rare-earth bond magnet, composition for rare-earth bond magnet, and process for producing rare-earth bond magnet
WO2001074395A3 (en) Amiodarone-containing parenteral solution
EP1044971A4 (en) Taxane derivatives
EP1106619A3 (en) Threading intercalator having oxidation-reduction activity

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF DISCLAIMER

PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended